Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.696
https://www.valueinhealthjournal.com/article/S1098-3015(14)02626-6/fulltext
Title :
Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02626-6&doi=10.1016/j.jval.2014.08.696
First page :
A344
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
118